Jakub Dobruch

Jakub Dobruch

Auto-generated profile, based on publicly available information

Jakub Dobruch

Centre of Postgraduate Medical Education, European Health Centre Otwock, Poland

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in Regulatory Peptides
Verified
Journal Article
Closed access
ACAgnieszka Cudnoch-Jedrzejewska
Agnieszka Cudnoch-Jedrzejewska
JDJakub Dobruch
Jakub Dobruch
LPLiana Puchalska
Liana Puchalska
ESEwa W.A. Szczepańska-Sadowska
Ewa W.A. Szczepańska-Sadowska

1 March 2019 in European Urology Focus
Verified
Journal Article
Open access
Andrea NecchiAndrea Necchi
Andrea Necchi
LMLuigi Mariani
Luigi Mariani
SVSalvatore Lo Vullo
Salvatore Lo Vullo
EYEvan Y. Yu
Evan Y. Yu
MWMichael E. Woods
Michael E. Woods
KHKees Hendricksen
Kees Hendricksen
Limited data is available on the role, and extent of, postchemotherapy lymphadenectomy (PC-LND) in patients with clinical evidence of pelvic (cN1-3) or retroperitoneal (RP) lymph node spread from urothelial bladder carcinoma. To compare the outcomes of operated versus nonoperated patients after first-line chemotherapy. Data from 34 centers was collected, totaling 522 patients, treated between January 2000 and June 2015. Criteria for patient selection were the following: bladder primary tumor, lymph node metastases (pelvic±RP) only, first-line platinum-based chemotherapy given. LND (with cystectomy) versus observation after first-line chemotherapy for metastatic urothelial bladder carcinoma. Overall survival (OS) was the primary endpoint. Multiple propensity score techniques were adopted, including 1:1 propensity score matching and inverse probability of treatment weighting. Additionally, the inverse probability of treatment weighting analysis was performed with the inclusion of the covariates, that is, with doubly robust estimation. Overall, 242 (46.4%) patients received PC-LND and 280 (53.6%) observation after chemotherapy. There were 177 (33.9%) and 345 (66.1%) patients with either RP or pelvic LND only, respectively. Doubly robust estimation-adjusted comparison was not significant for improved OS for PC-LND (hazard ratio [HR]: 0.86, 95% confidence interval [CI]: 0.56-1.31, p=0.479), confirmed by matched analysis (HR: 0.91, 95% CI: 0.60-1.36, p=0.628). This was also observed in the RP subgroup (HR: 1.12, 95% CI: 0.68-1.84). The retrospective nature of the data and the heterogeneous patient population were the major limitations. Although there were substantial differences between the two groups, after accounting for major confounders we report a nonsignificant OS difference with PC-LND compared with observation only. These findings may be hypothesis-generating for future prospective trials. We found no differences in survival by adding postchemotherapy lymphadenectomy in patients with pelvic or retroperitoneal lymph node metastatic bladder cancer. The indication to perform postchemotherapy lymphadenectomy in the most suitable patients requires additional studies.

27 January 2022 in EXCLI Journal
Verified
Journal Article
Open access
BHBartosz Horosz
Bartosz Horosz
KBKatarzyna Białowolska
Katarzyna Białowolska
AKAnna Kociuba
Anna Kociuba
JDJakub Dobruch
Jakub Dobruch
MMMałgorzata Malec-Milewska
Małgorzata Malec-Milewska
A minimally invasive approach to radical prostatectomy offers improved ambulation and discharge times. Postoperative pain control is one of the key factors that facilitates rapid recovery. With the aim to assure adequate analgesia and minimize the use of opioids, application of truncal nerve blocks has been proposed in a number of endoscopic procedures. The aim of this double-blind, placebo-controlled study was to evaluate the efficacy of bilateral posterior quadratus lumborum block (pQLB) in alleviating pain and reducing postoperative opioid demand in patients following endoscopic extraperitoneal and laparoscopic prostatectomy. We enrolled 50 patients who were diagnosed with prostate cancer and scheduled for prostatectomy. They were randomized to receive preoperative, ultrasound-guided pQLB with the use of either 30 ml of 0.375 % ropivacaine (ropivacaine group) or 30 ml of 0.9 % NaCl (placebo group). Our primary endpoint was opioid consumption in the first 24 hours after surgery. Secondary endpoints were pain intensity at predefined timepoints and the incidence of nausea and vomiting and pruritus. No differences were detected between the ropivacaine and placebo groups in intravenous oxycodone consumption during the first 24 hours after surgery. Similarly, there were no differences in pain intensity at any of the timepoints assessed. The rate of nausea and vomiting was equal in both groups and pruritus was not observed. Application of bilateral pQLB does not reduce opioid consumption after minimally invasive prostatectomy.

26 February 2014 in Videosurgery and Other Miniinvasive Techniques
Verified
Journal Article
Open access
JDJakub Dobruch
Jakub Dobruch
SPSebastian Piotrowicz
Sebastian Piotrowicz
MSMichal Skrzypczyk
Michal Skrzypczyk
TGTomasz Gołąbek
Tomasz Gołąbek
PCPiotr Chłosta
Piotr Chłosta
ABAndrzej Borówka
Andrzej Borówka
Introduction: Extended pelvic lymph node dissection (ePLND) is advised to complement radical prostatectomy (RP) in intermediate and high risk prostate cancer patients. Aim : To assess the risk of nodal involvement in patients subjected to laparoscopic radical prostatectomy and to...

11 March 2016 in European Urology Supplements
Verified
Journal Article
Closed access
AAA. Aziz
A. Aziz
PBP. Bes
P. Bes
FCF.K Chun
F.K Chun
JDJ. Dobruch
J. Dobruch
LKL.A Kluth
L.A Kluth
EXE.N. Xylinas
E.N. Xylinas

1 October 2013 in European Urology Supplements
Verified
Journal Article
Closed access
LNLukasz Nyk
Lukasz Nyk
JDJ. Dobruch
J. Dobruch
TDT. Dzik
T. Dzik
MWM. Wysocki
M. Wysocki
TGT. Gołąbek
T. Gołąbek
ABA. Borówka
A. Borówka